Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 13

1.

α-Synuclein fibril-induced inclusion spread in rats and mice correlates with dopaminergic Neurodegeneration.

Abdelmotilib H, Maltbie T, Delic V, Liu Z, Hu X, Fraser KB, Moehle MS, Stoyka L, Anabtawi N, Krendelchtchikova V, Volpicelli-Daley LA, West A.

Neurobiol Dis. 2017 Sep;105:84-98. doi: 10.1016/j.nbd.2017.05.014. Epub 2017 May 30.

2.

Development of an Ad5H3 Chimera Using the "Antigen Capsid-Incorporation" Strategy for an Alternative Vaccination Approach.

Gu L, Icyuz M, Krendelchtchikova V, Krendelchtchikov A, Johnston AE, Matthews QL.

Open Virol J. 2016 Apr 26;10:10-20. doi: 10.2174/1874357901610010010. eCollection 2016.

3.

Adenoviral vectors elicit humoral immunity against variable loop 2 of clade C HIV-1 gp120 via "Antigen Capsid-Incorporation" strategy.

Gu L, Krendelchtchikova V, Krendelchtchikov A, Farrow AL, Derdeyn CA, Matthews QL.

Virology. 2016 Jan;487:75-84. doi: 10.1016/j.virol.2015.10.010. Epub 2015 Oct 23.

4.

Immunization with Hexon modified adenoviral vectors integrated with gp83 epitope provides protection against Trypanosoma cruzi infection.

Farrow AL, Rachakonda G, Gu L, Krendelchtchikova V, Nde PN, Pratap S, Lima MF, Villalta F, Matthews QL.

PLoS Negl Trop Dis. 2014 Aug 21;8(8):e3089. doi: 10.1371/journal.pntd.0003089. eCollection 2014 Aug.

5.

A recombinant adenovirus-based vector elicits a specific humoral immune response against the V3 loop of HIV-1 gp120 in mice through the "Antigen Capsid-Incorporation" strategy.

Gu L, Krendelchtchikova V, Krendelchtchikov A, Oster RA, Fujihashi K, Matthews QL.

Virol J. 2014 Jun 16;11:112. doi: 10.1186/1743-422X-11-112.

6.

Using multivalent adenoviral vectors for HIV vaccination.

Gu L, Li ZC, Krendelchtchikov A, Krendelchtchikova V, Wu H, Matthews QL.

PLoS One. 2013;8(3):e60347. doi: 10.1371/journal.pone.0060347. Epub 2013 Mar 28.

7.

Interplay of acute and persistent infections caused by Venezuelan equine encephalitis virus encoding mutated capsid protein.

Atasheva S, Krendelchtchikova V, Liopo A, Frolova E, Frolov I.

J Virol. 2010 Oct;84(19):10004-15. doi: 10.1128/JVI.01151-10. Epub 2010 Jul 28.

8.

Experimental cancer therapy using restoration of NAD+ -linked 15-hydroxyprostaglandin dehydrogenase expression.

Kaliberova LN, Kusmartsev SA, Krendelchtchikova V, Stockard CR, Grizzle WE, Buchsbaum DJ, Kaliberov SA.

Mol Cancer Ther. 2009 Nov;8(11):3130-9. doi: 10.1158/1535-7163.MCT-09-0270. Epub 2009 Nov 3.

9.

CRAdRGDflt-IL24 virotherapy in combination with chemotherapy of experimental glioma.

Kaliberova LN, Krendelchtchikova V, Harmon DK, Stockard CR, Petersen AS, Markert JM, Gillespie GY, Grizzle WE, Buchsbaum DJ, Kaliberov SA.

Cancer Gene Ther. 2009 Oct;16(10):794-805. doi: 10.1038/cgt.2009.23. Epub 2009 Apr 10.

10.

Molecular chemotherapy of pancreatic cancer using novel mutant bacterial cytosine deaminase gene.

Kaliberova LN, Della Manna DL, Krendelchtchikova V, Black ME, Buchsbaum DJ, Kaliberov SA.

Mol Cancer Ther. 2008 Sep;7(9):2845-54. doi: 10.1158/1535-7163.MCT-08-0347.

11.

Mutation of Escherichia coli cytosine deaminase significantly enhances molecular chemotherapy of human glioma.

Kaliberov SA, Market JM, Gillespie GY, Krendelchtchikova V, Della Manna D, Sellers JC, Kaliberova LN, Black ME, Buchsbaum DJ.

Gene Ther. 2007 Jul;14(14):1111-9. Epub 2007 May 10.

PMID:
17495948
12.

Combination of cytosine deaminase suicide gene expression with DR5 antibody treatment increases cancer cell cytotoxicity.

Kaliberov SA, Chiz S, Kaliberova LN, Krendelchtchikova V, Della Manna D, Zhou T, Buchsbaum DJ.

Cancer Gene Ther. 2006 Feb;13(2):203-14.

PMID:
16082379
13.

Modulation of adenovirus vector tropism via incorporation of polypeptide ligands into the fiber protein.

Belousova N, Krendelchtchikova V, Curiel DT, Krasnykh V.

J Virol. 2002 Sep;76(17):8621-31.

Supplemental Content

Loading ...
Support Center